MedPath

Role of flow cytometry in the assessment of restoration of hematopoiesis during standard Exjade® treatment in patients with low- intermediate I risk myelodysplastisc syndromes, a pilot study

Completed
Conditions
n.a.
10018849
Registration Number
NL-OMON35738
Lead Sponsor
Vrije Universiteit Medisch Centrum
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
20
Inclusion Criteria

MDS type low and intermediate risk, supportive care treatment, start Exjade®

Exclusion Criteria

Comorbidity, anaemia MDS unrelated, previous treatment with Exjade®

Study & Design

Study Type
Observational invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>see above</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>See above</p><br>
© Copyright 2025. All Rights Reserved by MedPath